<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00063089</url>
  </required_header>
  <id_info>
    <org_study_id>Nabi-1407</org_study_id>
    <nct_id>NCT00063089</nct_id>
  </id_info>
  <brief_title>Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever</brief_title>
  <official_title>Initial Safety and Pharmacokinetics Trial of Immune Globulin to Staphylococcus Aureus Capsule Polysaccharide (Altastaph) in Subjects With S. Aureus Bacteremia and Persistent Fever</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nabi Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nabi Biopharmaceuticals</source>
  <brief_summary>
    <textblock>
      Altastaph has been developed to help the removal of S. aureus from the bloodstream. The main&#xD;
      objective of this study will be to test the safety and behavior of Altastaph in patients with&#xD;
      S.aureus bacteremia and continuing fever&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Staphylococcus aureus has been recognized as an important community - acquired and nosocomial&#xD;
      pathogen. Because it is a common cause of osteomyelitis, endocarditis, and meningitis, S.&#xD;
      aureus infections lead to considerable morbidity and mortality. The main objective of this&#xD;
      study will be to test the safety and pharmacokinetics of Altastaph in patients with S. aureus&#xD;
      bacteremia and persistent fever. This study will also assess the efficacy of Altastaph versus&#xD;
      control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>6 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Staphylococcal Infections</condition>
  <arm_group>
    <arm_group_label>altastaph</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S. aureus Immune Globulin Intravenous (Human) 5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.45% Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S. aureus Immune Globulin Intravenous (Human) 5%</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>altastaph</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female greater than or equal to 7 years of age&#xD;
&#xD;
          -  Weight less then or equal to 150 kilograms&#xD;
&#xD;
          -  Subjects willing to complete the full duration of the study, including the follow up&#xD;
             visit to day 42&#xD;
&#xD;
          -  Life expectancy will enable the subject to complete the duration of the study&#xD;
&#xD;
          -  Female subjects of child-bearing potential, negative serum pregnancy test prior to the&#xD;
             first infusion of study material. Female subjects of child-bearing potential must&#xD;
             agree to use an effective method of birth control throughout the study. Abstinence is&#xD;
             not considered an adequate birth control measure. Female subjects of non-child-bearing&#xD;
             potential must have history of hysterectomy, bilateral surgical or radiation-induced&#xD;
             oophorectomy, tubal ligation or evidence of post menopausal status&#xD;
&#xD;
          -  Subject, legal guardian(s) or medical power of attorney must have given written&#xD;
             informed consent/ assent&#xD;
&#xD;
          -  S. aureus bacteremia and persistent fever. S. aureus bacteremia is defined as the&#xD;
             first blood culture positive for S. aureus (index blood culture). Persistent fever&#xD;
             (qualifying fever) is defined as a temperature (greater then or equal to 100.4F or&#xD;
             greater then or equal to 38C) occuring at least 24 hours after the index temperature&#xD;
             was recorded and after the index blood culture was drawn&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC) greater then or equal to 500 x 10^9 cells/L&#xD;
&#xD;
          -  Subjects with malignancies may participate if:(1) The malignancy is a solid tumor&#xD;
             (i.e. not lymphoma, leukemia, etc.)(2) The tumor has not metastasized to the bone&#xD;
             marrow&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or previous anaphylaxis to polysaccharide or&#xD;
             polysaccharide-conjugate vaccines or to any component of Altastaph&#xD;
&#xD;
          -  Profound disability, assessed by the investigator, which would prevent participation&#xD;
             in the study&#xD;
&#xD;
          -  Known IgA deficiency&#xD;
&#xD;
          -  Known HIV infection with CD4 count &lt; 200 cells/L&#xD;
&#xD;
          -  Presence of any conditions which, in the opinion of the investigator, places the&#xD;
             subject at undo risk or potentially jeopardizes the quality of the data to be&#xD;
             generated&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Use of investigational drug or biologic in the four weeks prior to screening and&#xD;
             during the study. The only exception is use of investigational antineoplastic product&#xD;
             if, and only if: (1) The product is not expected to result in sever and prolonged&#xD;
             immunosuppression (2) The product is, itself, not immunologically-based (e.g.&#xD;
             anti-tumor/ monoclonal antibodies, cancer vaccines or interleukins&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.nabi.com</url>
    <description>Nabi Biopharmaceuticals</description>
  </link>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>June 19, 2003</study_first_submitted>
  <study_first_submitted_qc>June 19, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2003</study_first_posted>
  <last_update_submitted>May 10, 2012</last_update_submitted>
  <last_update_submitted_qc>May 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staphylococcal infection</keyword>
  <keyword>Gram positive bacteria</keyword>
  <keyword>Staphylococcus</keyword>
  <keyword>Staphylococcus aureus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

